Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244712 · ClinicalTrials.gov registry record · Phase 4
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 688
- Enrollment target
NCT00244712 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 688 participants.
The verdict
NCT00244712, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 688 participants
- Enrollment target
Study Summary
This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA (lopinavir/ritonavir) over 96 weeks
Interventions
- DRUG abacavir/lamivudine
- DRUG emtricitabine/tenofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 688 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244712
The ClinicalTrials.gov registry entry for NCT00244712 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 688 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which abacavir/lamivudine is the first listed.
NCT00244712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244712 about?
NCT00244712 is a clinical study titled "Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV". This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA (lopinavir/ritonavir) over 96 weeks
What is the current status of trial NCT00244712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 688 participants. The study started on 2005-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00244712?
The interventions under investigation include: abacavir/lamivudine (DRUG), emtricitabine/tenofovir (DRUG).
Who is sponsoring clinical trial NCT00244712?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.